We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$308M
AUM Growth
-$38.9M
Cap. Flow
-$25.7M
Cap. Flow %
-8.35%
Top 10 Hldgs %
52.97%
Holding
98
New
10
Increased
19
Reduced
20
Closed
18

Top Buys

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$4.11M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$4M
3
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$2.94M
4
ETNB
89bio
ETNB
+$2.85M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.16M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$11.3M
2
KURA icon
Kura Oncology
KURA
+$5.64M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.92M
4
CGEN icon
Compugen
CGEN
+$3.73M
5
AKBA icon
Akebia Therapeutics
AKBA
+$3.69M

Sector Composition

Rank Sector Weight
1 Healthcare 83.1%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASLN
76
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$164K 0.05%
2,152
– –
LCTX icon
77
Lineage Cell Therapeutics
LCTX
$278M
$89K 0.03%
95,000
– –
CRDF icon
78
Cardiff Oncology
CRDF
$77.2M
$71K 0.02%
+5,000
New +$33K
AUTL
79
Autolus Therapeutics
AUTL
$562M
– –
-64,235
Closed -$1.03M
AVTX icon
80
Avalo Therapeutics
AVTX
$983M
– –
-110
Closed -$827K
CRBP icon
81
Corbus Pharmaceuticals
CRBP
$190M
– –
-3,602
Closed -$907K
CTMX icon
82
CytomX Therapeutics
CTMX
$754M
– –
-6,100
Closed -$51K
CYPH
83
Cypherpunk Technologies Inc
CYPH
$73.3M
– –
-27,500
Closed -$575K
RIGL icon
84
Rigel Pharmaceuticals
RIGL
$750M
– –
-15,770
Closed -$289K
SLNO
85
DELISTED
Soleno Therapeutics
SLNO
– –
-24,833
Closed -$827K
SYBX
86
DELISTED
Synlogic
SYBX
– –
-26,906
Closed -$819K
RNTX
87
Rein Therapeutics
RNTX
$69.9M
– –
-22,500
Closed -$531K
GRTS
88
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-50,000
Closed -$332K
MORF
89
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-30,000
Closed -$812K
CBAY
90
DELISTED
Cymabay Therapeutics
CBAY
– –
-165,600
Closed -$578K
MRTX
91
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-21,893
Closed -$2.5M
TCRR
92
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-46,183
Closed -$709K
PRVB
93
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-25,000
Closed -$353K
TPTX
94
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-23,210
Closed -$1.5M
GNCA
95
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-524,664
Closed -$1.21M
ZGNX
96
DELISTED
Zogenix, Inc.
ZGNX
– –
-50,749
Closed -$1.37M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, DAFNA Capital Management held 98 positions worth $308M, down 11% from $347M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management withdrew a net $25.7M in Q3 2020, closing 18 positions and reducing 20 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $2.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 88% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in IDEAYA Biosciences worth $4.17M.

  • DAFNA Capital Management's largest Q3 2020 buy was IDEAYA Biosciences: 331,661 shares worth $4.17M.
  • DAFNA Capital Management added most to Arcturus Therapeutics in Q3 2020, an estimated $4M increase.
  • DAFNA Capital Management's biggest Q3 2020 reduction was Arena Pharmaceuticals Inc, cutting an estimated $11.3M.
  • DAFNA Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $2.5M.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $308M portfolio in Q3 2020.
  • DAFNA Capital Management opened 10 new positions and closed 18 in Q3 2020.
  • DAFNA Capital Management's portfolio value fell 11% quarter-over-quarter to $308M.

Based on DAFNA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.